¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple inhibition analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • multiple epiphyseal dysplasia
    ¹µ»À³¡Çü¼ºÀÌ»ó, ´Ù¹ß°ñ´ÜÇü¼ºÀÌ»ó
  • multiple excitation
    ´Ù¹ßÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple field irradiation
    ¿©·¯¿µ¿ªÁ¶»ç
  • multiple fission
    ¹µºÐ¿­, ´ÙÁߺп­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple infection
    º¹¼ö°¨¿°, ¿©·¯¹ø°¨¿°
  • multiple intestinal polyposis
    ´Ù¹ßÀåÆú¸³Áõ
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ, ´Ù¹ßÀåÁßøÁõ
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • control analysis
    ÁöµµºÐ¼®
  • cost-benefit analysis
    ºñ¿ëÆíÀͺм®
  • cost-effectiveness analysis
    ºñ¿ëÈ¿°úºÐ¼®
  • cost-efficiency analysis
    ºñ¿ëÈ¿À²ºÐ¼®
  • cost-utility analysis
    ºñ¿ëÈ¿¿ëºÐ¼®
  • decision analysis
    ÀÇ»ç°áÁ¤ºÐ¼®
  • discriminant analysis
    ÆÇº°ºÐ¼®
  • distributive analysis
    ºÐÆ÷ºÐ¼®
  • gene analysis
    À¯ÀüÀںм®
  • image analysis
    ¿µ»óºÐ¼®
  • multivariate analysis
    ´Ùº¯·®ºÐ¼®, ´Ù¿äÀκм®
  • nephelometric analysis
    ȥŹºÐ¼®
  • path analysis
    °æ·ÎºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®
  • principal component analysis
    ÁÖ¼ººÐºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • PETINIA => particle-enhanced turbidimetric inhibition immunoassay
    ÀÔÀÚÁõ´ëºñʾïÁ¦¸é¿ªÃøÁ¤(¹ý)
  • afferent inhibition
    ±¸½É¼º ¾ïÁ¦(Ï´ãýàõåäð¤)
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦(¹ÝÀÀ), ÀúÁö(¹ÝÀÀ).
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test
    ÀúÁö½ÃÇè(îÁò­ãËúÐ).
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
  • inhibition test, antiglobulin
    Çױ۷κҸ° ¾ïÁ¦½ÃÇè, Çױ۷κҸ° ÀúÁö½ÃÇè
  • inhibition test, fluorescence
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • inhibition test, hemagglutination
    Ç÷±¸ÀÀÁý ¾ïÁ¦½ÃÇè, Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test, migration
    À¯ÁÖ¾ïÁ¦½ÃÇè, À¯ÁÖÀúÁö½ÃÇè
  • inhibition zone
    ¾ïÁ¦´ë(åäð¤Óá).
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
  • inhibition, allogeneic
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • inhibition, contact
    Á¢Ã˼º Áõ½Ä¾ïÁ¦
  • inhibition, fertility
    FÀÎÀÚ Àü´ÞÀúÁö, ¼öÅÂÀÎÀÚ Àü´ÞÀúÁö
  • interal inhibition
    Ãø¹æ¾ïÁ¦(ö°Û°åäð¤).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cumulative feedback inhibition
    ´©Àû(׫îÝ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • density inhibition
    "¹ÐµµÀúÇØ(ÚËÓøîÁúª), (ÔÒ) contact inhibition"
  • end-product inhibition
    Á¾»ê¹° ÀúÇØ (ðûß§ÚªîÁúª)
  • enzyme multiplicity feedback inhibition
    È¿¼Ò ´Ù¾ç¼º(ý£áÈÒýåÆàõ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • feedback inhibition
    µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ½ÃÇè(ãËúÐ)
  • hemagglutination inhibition
    "(Àû,îå)Ç÷±¸(úìϹ) ÀÀÁý ÀúÇØ(ëêó¢îÁúª)"
  • hyperbolic inhibition
    ½Ö°î¼± ÀúÇØ(äªÍØàÊîÁúª)
  • immunological inhibition
    ¸é¿ª ÀúÇØ(Øóæ¹îÁúª)
  • inhibition
    ÀúÇØ(îÁúª)
  • inhibition coefficient
    ÀúÇØ°è¼ö(îÁúªÌõâ¦)
  • inhibition constant
    ÀúÇØ»ó¼ö(îÁúªßÈâ¦)
  • inhibition index
    ÀúÇØÁö¼ö(îÁúªò¦â¦)
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
  • inhibition zone
    ÀúÇØ¿ª(îÁúªæ´)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AGPI agar gel precipitin inhibition
CFI chemotactic-factor inactivator; closed-clenched fist injury; color flow imaging; complement fixation...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
CIN central inhibition; cervical intraepithelial neoplasia; chronic interstitial nephritis
CMI carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IOR Inhibition of return
ICI Intracortical inhibition
LI Latent Inhibition
LMI Leucocyte Migration Inhibition
LMIT Leucocyte Migration Inhibition Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mixed dentition analysis
    È¥ÇÕ Ä¡¿­±âÀÇ ¾Ç±Ã °ø°£ ºÐ¼®
    È¥ÇÕ Ä¡¿­±â ±³ÇÕÀº ¿µ±¸ Á¦1 ´ë±¸Ä¡°¡ ¸ÍÃâÇÏ´Â 6-7¼¼ºÎÅÍ Çü¼ºµÈ´Ù. ½ÃÁø ¹× ±¸°­ ¹æ»ç¼±ÇÐÀû °Ë»çÀÇ È°¿ëÀ» ÅëÇØ ¿µ±¸Ä¡ ¸ÍÃâ ¼ø¼­¸¦ »ìÆìº¸´Â °ÍÀº Á¤»ó ±³ÇÕ Çü¼ºÀÇ °¡´É¼º ÆÇ´Ü¿¡ À¯È¿ÇÑ Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù.
  • occlusal analysis
    ±³ÇÕ ºÐ¼®
    ±³Çձ⿡ ÀåÂøµÈ ¸ðÇüÀÇ ±³ÇÕ °ü°è¸¦ Æò°¡ÇÏ´Â ±³ÇÕ.
  • qualitative analysis
    Á¤¼º ºÐ¼®
    È­ÇÐ ºÐ¼®¹ý Áß¿¡¼­ ½Ã·á°¡ ¾î¶² ¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´ÂÁö ¾Ë¾Æ³»±â À§ÇÑ ºÐ¼®¹ýÀÇ ÃÑĪ. ÀϹÝÀûÀ¸·Î Á¤·® ºÐ¼®À» Çϱâ Àü¿¡ Á¤¼º ºÐ¼®À» ÇÏ°Ô µÈ´Ù. ¹°ÁúÀ» ±¸¼ºÇϰí ÀÖ´Â È­ÇÐÁ¾
  • script analysis
    °¢º» ºÐ¼®
    »çȸ¿¡ Âü¿©ÇÒ ¶§ Çൿ ¾ç»óÀÇ Æ²ÀÎ °¢º»ÀÌ ¸¸µé¾îÁö´Â °úÁ¤¿¡ ´ëÇÑ ºÐ¼®.
  • sequential analysis
    ¼øÂ÷Àû ºÐ¼®
  • space analysis
    °ø°£ ºÐ¼®
  • spectral analysis
    ½ºÆåÆ®·³ ºÐ¼®
    ¹°ÁúÀÇ ¹æÃâ ½ºÆåÆ®·³ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¶»çÇÏ¿©, ±× ¼Ó¿¡ ÀÖ´Â ¼ººÐ ¿ø¼Ò³ª È­ÇÕ¹°ÀÇ Á¾·ù¿Í ¾çÀ» ÆÇÁ¤ÇÏ´Â ¹æ¹ý. ºÐ±¤ È­ÇÐ ºÐ¼®À̶ó°íµµ ÇÑ´Ù. 19¼¼±â Áß¿±¿¡ R. ºÐÁ¨ÀÌ G. ۸£È÷È£ÇÁÀÇ Çù·ÂÀ» ¾ò¾î È®¸³½ÃŲ ½ÇÇè ±â¼úÀ̸ç, º¸ÅëÀÇ È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© Á¶ÀÛÀÌ ºü¸£°í, ¼Ò·®ÀÇ ½Ã·á·Îµµ ºÐ¼®ÀÌ °¡´ÉÇÑ ÀÌÁ¡ÀÌ ÀÖ´Ù. ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °Í°ú, Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ °ÍÀÇ µÎ °¡Áö·Î Å©°Ô ³ª´­ ¼ö ÀÖ´Ù. ¡¼¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ¿øÀÚ¿¡¼­ ¹æÃâµÇ´Â ºûÀÇ ½ºÆåÆ®·³ÀÌ °¢ ¿ø¼Ò¿¡ µû¶ó °íÀ¯ÇÔÀ» ÀÌ¿ëÇÔÀ¸·Î½á, ½Ã·á¸¦ ¹ß±¤½ÃÄÑ ½ºÆåÆ®·³À» °Ë»çÇϰí, ¹Ì¸® Á¶»çÇÏ¿© µÐ Ç¥ÁØ ½Ã·áÀÇ ¹æÃâ ½ºÆåÆ®·³À» ±âÃÊ·Î ¼ººÐ ¿ø¼ÒÀÇ Á¾·ù³ª ¾çÀ» ¾Ë¾Æ³»´Â ¹æ¹ýÀÌ´Ù. °ËÃâÀÇ Á¤¹Ðµµ´Â ¿ø¼Ò¿¡ µû¶ó ´Ù¸£Áö¸¸, ÀϹÝÀûÀ¸·Î È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© °¨µµ°¡ ³ô°í, ƯÈ÷ ±Ý¼Ó¿¡ ¹Ì·®À¸·Î ÇÔÀ¯µÇ¾î ÀÖ´Â ºÒ¼ø¹° ¿ø¼ÒÀÇ ¹ß°ßÀ̳ª Á¤·® µî¿¡´Â ÁÁÀº °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù. ½Ã·á¸¦ ¹ß±¤½ÃŰ´Â µ¥´Â º¸Åë ½Ã·á¸¦ ÇÑÂÊ ±ØÀ¸·Î ÇÏ´Â ¾ÆÅ© ¹æÀüÀ̳ª, ±âü »óÅÂÀÇ ½Ã·á¸¦ ¹æÀü°ü¿¡ ä¿ö¼­ ¹æÀü½ÃŰ´Â ¹æ¹ýÀÌ ÀÌ¿ëµÈ´Ù. ¾ËÄ®¸® ±Ý¼ÓÀ̳ª ¾ËÄ®¸®Åä ±Ý¼Ó¿¡ ´ëÇÑ ºÒ²É ¹ÝÀÀÀ» ÀÌ¿ëÇÑ ºÒ²É ½ÃÇèµµ ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °£´ÜÇÑ ºÐ±¤ ºÐ¼®À̶ó ÇÒ ¼ö ÀÖ´Ù. ¡¼Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ±âü³ª ¿ë¾×¿¡ ¿¬¼Ó ½ºÆåÆ®·³À» °¡Áø ºûÀ» Á¶»çÇϸé, ±× ¼Ó¿¡ Á¸ÀçÇϴ Ȭ ¿ø¼ÒÁúÀ̳ª È­ÇÕ¹°ÀÌ °¢°¢ ƯÀ¯ÇÑ ÆÄÀåÀÇ ºûÀ» ¼±ÅÃÀûÀ¸·Î Èí¼öÇϹǷÎ, Åõ°ú±¤ÀÇ ½ºÆåÆ®·³¿¡´Â ¹°ÁúÀÇ Á¾·ù¿¡ µû¶ó ƯÀ¯ÇÑ ¹è¿­À» °¡Áø Èí¼ö ¼±ÀÌ ³ªÅ¸³­´Ù. µû¶ó¼­, ¾î¶² ¾ç ¶Ç´Â µÎ²²ÀÇ ¼ø¼öÇÑ ¹°ÁúÀÇ Èí¼ö ½ºÆåÆ®·³À» ¸¹ÀÌ °®Ãß°í ÀÖÀ¸¸é, À̰ÍÀ» ±âÃÊ·Î ÇÏ¿© ¹ÌÁö ½Ã·áÀÇ Á¤¼º ºÐ¼®, ¾Ë°í ÀÖ´Â ½Ã·áÀÇ Á¤·® ºÐ¼®, ½Ã·á ¼Ó¿¡ ÀÖ´Â ºÒ¼ø¹°ÀÇ ¹ß°ß ¹× Á¤·®ÇÒ ¼ö ÀÖ´Ù. À̰ÍÀÌ Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ±¤ ºÐ¼®À̸ç, ƯÈ÷ ¿ë¾× ¼Ó¿¡ Á¸ÀçÇÏ´Â ºñŸ¹Î·ùÀÇ Á¤·® µîÀº ÀÌ ¹æ¹ýÀ» »ç¿ëÇÏ¸é ½±°Ô ¾Ë ¼ö ÀÖ´Ù. ºÐ±¤ ºÐ¼®Àº ½ºÆåÆ®·³ ºÐ¼®À̶ó°íµµ Çϴµ¥, ½ºÆåÆ®·³ ºÐ¼®À̶ó°í ÇÒ ¶§´Â ÀÌ»ó°ú °°Àº ºÐ¼® È­Çп¡ÀÇ ÀÀ¿ë ¿Ü¿¡, ¹°ÁúÀÇ ¹æÃâ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¤¹ÐÈ÷ ÃøÁ¤, ÇØ¼®ÇÏ¿© ¹°ÁúÀÇ ¿¡³ÊÁö ÁØÀ§, ÀüÀÌ È®·ü, ºÐÀÚÀÇ °áÇÕ °£°ÝÀ̳ª ºÐÀÚ ±¸Á¶ÀÇ °áÁ¤ µî¿¡µµ ÀÌ¿ëµÈ´Ù.
  • spectrophotometric analysis
    ºÐ±¤ ±¤µµ ºÐ¼®
  • statistic :

    statistical analysis

    Åë°èÀû ºÐ¼®
  • stress analysis
    ÀÀ·Â ºÐ¼®
  • synovial fluid analysis
    Ȱ¾× ºÐ¼®
  • thermal analysis
    ¿­ ºÐ¼®
  • urine analysis
    ¿ä °Ë»ç, ¼Òº¯ ºÐ¼®
    µ¿ÀǾî=urinalysis.
  • volumetric analysis
    ¿ë·® ºÐ¼®
  • water analysis
    ¼öºÐ¼®, ¼öÁú ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
miscarriages, multiple, chromosomes in Couples who have had more than one miscarriage have about a 5% chance that one member of the couple is carrying a chromsome translocation responsible for the miscarriages.
(12 Dec 1998)
multiple Manifold, occurring in or affecting various parts of the body at once.
Origin: L. Multiplex
(18 Nov 1997)
multiple alcohol An alcohol containing more than one OH group.
(05 Mar 2000)
multiple amputation Amputation of two or more limbs or parts of limbs performed at the same operation.
(05 Mar 2000)
multiple anchorage Anchorage in which more than one type of resistance unit is utilised.
Synonym: reinforced anchorage.
(05 Mar 2000)
multiple birth offspring The offspring in multiple pregnancies (pregnancy, multiple): twins, triplets, quadruplets, quintuplets, etc.
(12 Dec 1998)
multiple carboxylase deficiency Abnormalities in carbohydrate and branched-chain amino acid catabolism that are responsive to biotin therapy. It may be due to deficiency of propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, biotinidase, or propionyl-CoA carboxylase, methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.
(12 Dec 1998)
multiple chemical sensitivity An acquired disorder characterised by recurrent symptoms, referable to multiple organ systems, occurring in response to demonstrable exposure to many chemically unrelated compounds at doses far below those established in the general population to cause harmful effects. No single widely accepted test of physiologic function can be shown to correlate with symptoms. (cullen mr. The worker with multiple chemical sensitivities: an overview. Occup med 1987;2(4):655-61)
(12 Dec 1998)
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á